One of the treatments that’s been talked up by President Donald Trump for COVID-19 — a combination of the antimalarial drug hydroxychloroquine and azithromycin, an antibiotic — is the subject of a nationwide study with UW Medicine playing a role.
The Phase 2b clinical trial, sponsored by the National Institute of Allergy and Infectious Disease at the National Institutes of Health, will involve 2,000 outpatients who have tested positive for COVID-19 and are in the early stages of treatment.
“We know from a number of different other kinds of infections that if antiviral treatment is going to be effective, it tends to be most effective if it’s given very early on,” Ann Collier, a professor at the University of Washington’s School of Medicine, said in a video about the study.
